United-Guardian Inc. reported a decrease in both sales and net income for the first quarter of 2025 compared to the same period in 2024. Sales dropped by 24%, from $3.25 million in Q1 2024 to $2.48 million in Q1 2025. Net income decreased to $560,895, down from $925,442 in the previous year. The company noted a significant increase in sales of pharmaceuticals and medical lubricants, with a 23% rise in pharmaceutical sales and a 43% increase in medical lubricants sales. This improvement was attributed to the resolution of a supply disruption of Renacidin® that had affected sales in early 2024. United-Guardian Inc. is expanding its focus on brand awareness and distribution, especially in its Lubrajel® line of hydrogels, which saw a 101% increase in sales for its distribution partners in Q1 2025. The company is also exploring potential growth in the hair care sector and is developing new products for the medical market. Additionally, efforts are underway to enhance the market presence of Renacidin by addressing awareness and availability challenges for healthcare practitioners and payers. The company is optimistic about signing a new marketing and distribution agreement with ASI for its cosmetic ingredients later this year.